Collecting duct carcinoma (Bellini duct carcinoma) is a rare and highly aggressive subtype of renal cell carcinoma originating from the renal medulla. It accounts for less than 1-2% of all renal cell carcinomas. It arises from the collecting duct epithelium and typically presents as a centrally located, infiltrative mass in the renal medulla. It shows significant morphological overlap with urothelial carcinoma and renal medullary carcinoma. Although imaging features are nonspecific, medullary location, prominent infiltrative growth pattern, hypoenhancement, and irregular borders are characteristic findings. Most patients present with advanced-stage disease at diagnosis, and prognosis is extremely poor with median survival of 12-30 months. It is unresponsive to standard clear cell RCC treatments; better responses have been reported with urothelial carcinoma protocols (cisplatin-based chemotherapy). Typically occurs between ages 40-70, with a 2-3 times male predominance.
Age Range
30-70
Peak Age
55
Gender
Male predominant
Prevalence
Rare
Collecting duct carcinoma is a malignancy arising from the epithelium of the collecting duct (Bellini duct), the distal segment of the nephron. Collecting ducts are concentrated in the renal medulla, which is why the tumor characteristically exhibits a medullary/central location. The high-grade pleomorphism of tumor cells and desmoplastic stromal reaction significantly influence imaging characteristics. The dense desmoplastic stroma (collagen-rich fibrotic tissue) causes the tumor to be poorly vascularized and appear hypointense/hypodense on contrast-enhanced imaging. Low signal intensity on T2-weighted MRI also results from this fibrotic stroma — the movement of free water molecules is restricted by collagen fibrils, shortening T2 relaxation time. The infiltrative growth pattern invades the renal sinus and perirenal tissues rather than forming a distinct mass; this feature resembles urothelial carcinoma. The tumor has a tendency for early lymph node and distant metastasis — both hematogenous and lymphatic spread are common. It shares molecular and morphological similarities with renal medullary carcinoma; however, medullary carcinoma is associated with sickle cell trait/disease and shows SMARCB1 (INI1) loss, while INI1 expression is generally preserved in collecting duct carcinoma. Making this distinction immunohistochemically is diagnostically important.
Centrally located mass in the renal medulla infiltrating the renal sinus and pelvicalyceal system, with irregular margins and poor enhancement. This finding is the most characteristic imaging feature of collecting duct carcinoma — showing medullary/central origin in contrast to the typical cortical/exophytic location of clear cell RCC. It shares a similar central growth pattern with urothelial carcinoma; however, collecting duct carcinoma shows a more prominent parenchymal component and more renal parenchymal invasion. This sign is guiding in the diagnosis of a rare tumor (<2% RCC) and directs the radiologist toward the differential diagnosis of urothelial carcinoma and medullary carcinoma.
On non-contrast CT, centrally located infiltrative mass with irregular margins in the renal medulla, isodense or mildly hypodense. The mass typically invades the renal sinus and narrows or obstructs the renal pelvis. Normal corticomedullary differentiation is lost. Heterogeneous internal structure is seen; necrotic areas, cystic degeneration, or punctate calcifications may be present. Tumor size at diagnosis is generally >4 cm, and determining true size boundaries is difficult due to surrounding tissue invasion.
Report Sentence
Centrally located heterogeneous isodense/hypodense mass with irregular margins infiltrating the renal sinus in the medullary region of the kidney; medullary location and infiltrative growth pattern primarily suggest collecting duct carcinoma and urothelial carcinoma.
In the corticomedullary phase, markedly hypoenhancing (hypovascular) infiltrative mass compared to the renal cortex. Enhancement pattern is heterogeneous; mild peripheral enhancement is seen while central portions remain markedly hypodense (necrosis). Invasion of the renal sinus and pelvicalyceal system is best evaluated in this phase. Renal vein thrombosis and perirenal fat invasion become more apparent in the contrast phase. The mass-parenchyma border is indistinct with gradual transition between normal parenchyma and tumor.
Report Sentence
Mass with markedly poor and heterogeneous enhancement compared to renal parenchyma in the corticomedullary phase, infiltrating the renal sinus and pelvicalyceal system; these hypovascular and infiltrative features are consistent with collecting duct carcinoma.
In the nephrographic phase, the mass continues to remain hypodense compared to renal parenchyma. The nephrographic phase allows best evaluation of the boundaries of infiltrative growth due to homogeneous enhancement of all renal parenchyma. Renal sinus fat invasion, pelvicalyceal system obliteration, and cortical destruction are most apparent in this phase. Perirenal extension, Gerota fascia involvement, and invasion of adjacent organs are evaluated. Retroperitoneal lymphadenopathy, renal vein, and IVC thrombosis should be systematically searched for in this phase.
Report Sentence
The mass remains persistently hypodense compared to renal parenchyma in the nephrographic phase, infiltrating the renal sinus and pelvicalyceal system; cortical destruction and perirenal extension are present.
On T2-weighted MR images, heterogeneous infiltrative mass with predominantly low-to-intermediate signal intensity in the renal medulla. Low T2 signal results from dense desmoplastic stroma and reflects high cellular density within the tumor. Focal areas of high T2 signal correspond to necrosis or cystic degeneration. Renal sinus invasion is well evaluated on T2 images — normal high-signal sinus fat is replaced by intermediate-signal tumor tissue. Corticomedullary differentiation is lost. Perinephric stranding and perirenal extension may be visible on T2.
Report Sentence
On T2-weighted images, predominantly hypointense, heterogeneous, infiltrative mass in the renal medulla with focal high signal areas suggesting necrosis; consistent with desmoplastic stroma-rich collecting duct carcinoma.
On diffusion-weighted images (DWI), marked signal increase at high b-values (b=800-1000 s/mm²) with corresponding low signal on ADC map (restricted diffusion) is seen. Restricted diffusion reflects high cellular density within the tumor and is an indicator of malignancy. ADC values are generally <1.0 x 10⁻³ mm²/s, significantly lower than clear cell RCC (typically 1.5-2.0 x 10⁻³ mm²/s). Necrotic areas do not show diffusion restriction (should not be confused with T2 shine-through). DWI provides additional information to conventional sequences in evaluating tumor boundaries.
Report Sentence
The mass shows marked diffusion restriction on diffusion-weighted images with low ADC values; this finding is consistent with high cellular density and supports malignancy.
On contrast-enhanced MRI, poor and heterogeneous enhancement is seen in the arterial phase. The tumor remains hypointense despite prominent enhancement of the renal cortex. Time-signal curve on dynamic contrast study shows a slowly rising (progressive) pattern — early intense enhancement (wash-in) is not seen. This finding is markedly different from the typical early arterial hypervascularity of clear cell RCC. Enhancement pattern generally shows time-dependent gradual increase (no washout) and this feature may overlap with papillary RCC.
Report Sentence
On contrast-enhanced MRI, the mass shows markedly poor enhancement compared to renal parenchyma in the arterial phase; this hypovascular feature is consistent with collecting duct carcinoma or papillary RCC.
On B-mode ultrasound, heterogeneous, predominantly hypoechoic solid mass located in the renal medulla. Renal sinus echogenicity is disrupted with normal sinus fat high echogenicity replaced by the tumor. Mass margins are irregular, and clear delineation between renal parenchyma and tumor is difficult. Echogenic focal areas may correspond to fibrosis or calcification within the tumor. Color Doppler generally shows a hypovascular pattern — in contrast to the typical hypervascularity of clear cell RCC. Hydronephrosis may result from obstruction of the pelvicalyceal system by infiltrative tumor growth.
Report Sentence
On B-mode ultrasound, heterogeneous, predominantly hypoechoic solid mass with irregular margins in the medullary region of the kidney infiltrating the renal sinus; hypovascular pattern is seen on color Doppler.
In the excretory phase, invasion and obstruction of the pelvicalyceal system by the tumor is best evaluated. Excretion of contrast by the collecting system demonstrates the relationship between tumor and urothelial surface. Calyceal obliteration, renal pelvis narrowing/obstruction, and proximal ureteral invasion are clearly seen in this phase. This finding creates significant overlap with urothelial carcinoma — both tumors invade the pelvicalyceal system and their differentiation on imaging can be difficult. Entrapped contrast pooling within the tumor may be visible.
Report Sentence
In the excretory phase, the tumor is seen invading the pelvicalyceal system causing calyceal obliteration and renal pelvis obstruction; the medullary-origin invasion pattern suggests collecting duct carcinoma.
Criteria
Centrally located infiltrative mass in the renal medulla, tubular/tubulopapillary architecture, prominent desmoplastic stroma, high-grade cytologic atypia. Immunohistochemically PAX8+, CK7+, CK34betaE12+, SMARCB1 (INI1) preserved. May partially express urothelial carcinoma markers (GATA3, p63 may be focally positive).
Distinct Features
Most common form. Characteristic medullary location, infiltrative growth, and dense desmoplastic stroma. On imaging, hypovascular, heterogeneous mass with irregular margins. Median survival 12-24 months. Usually diagnosed at advanced stage (stage III-IV). May show partial response to cisplatin-based chemotherapy.
Criteria
Spindle cell (sarkomatoid) component on a background of classic collecting duct carcinoma. Sarkomatoid component generally constitutes >20% of the tumor. Partial loss of epithelial markers (decreased CK expression), increased vimentin expression. Ki-67 proliferation index >50%.
Distinct Features
Most aggressive form — median survival 6-12 months. On imaging, prominent necrosis, larger tumor size, and more extensive extrarenal invasion. More heterogeneous internal structure and more prominent necrotic areas. Chemoresistant. Early recurrence after surgery. Immunotherapy trials are ongoing.
Criteria
Extracellular mucin accumulation on a background of classic collecting duct carcinoma. Prominent mucin positivity on PAS and Alcian blue staining. Mucin pools in tubular lumens and stroma. CK7+, CK20 variable, CDX2 negative (differentiation from colorectal metastasis).
Distinct Features
Rare variant. On imaging, cystic/mixed appearance may be seen due to mucin content — low density areas on CT, high T2 signal areas on MRI correspond to mucin pools. Prognosis is similar to or slightly better than classic type. Should not be confused with mucinous adenocarcinoma metastasis due to mucin content — differentiated by CDX2 negativity.
Criteria
Variant showing low-grade nuclear atypia and less desmoplastic stroma. Classification is controversial — some pathologists argue it should be classified as tubulocystic renal cell carcinoma or low-grade tubular neoplasia. WHO 2022 classification has opened debate about the independent existence of this variant.
Distinct Features
Extremely rare. On imaging may be better circumscribed, less infiltrative. May be diagnosed at smaller size. Prognosis is significantly better than classic type — 5-year survival >50%. Whether its existence as an independent entity is controversial in the pathology community.
Distinguishing Feature
Urothelial carcinoma grows from the mucosal surface (urothelial epithelium) and forms a polypoid mass into the lumen of the pelvicalyceal system; typical luminal filling defect is seen in the excretory phase. Collecting duct carcinoma grows from the renal medulla (from within the parenchyma) and shows a more prominent parenchymal component. While mucosal irregularity of the pelvicalyceal system is prominent in urothelial carcinoma, parenchymal infiltration and renal sinus invasion are more pronounced in collecting duct carcinoma. Clinically, gross hematuria is more common in urothelial carcinoma patients.
Distinguishing Feature
Renal medullary carcinoma is the diagnosis most confused with collecting duct carcinoma on imaging and pathology. Critical distinction: medullary carcinoma occurs almost exclusively in young patients (ages 10-40) with sickle cell trait/disease. Immunohistochemically, SMARCB1 (INI1) loss is pathognomonic for medullary carcinoma — INI1 is preserved in collecting duct carcinoma. On imaging, both tumors are medullary-located, infiltrative, hypovascular; however, medullary carcinoma typically presents at younger ages and with more rapid growth. Both show T2 hypointensity and diffusion restriction on MRI.
Distinguishing Feature
Clear cell RCC typically locates in the renal cortex (exophytic or endophytic) and shows prominent hypervascularity (bright enhancement) in the arterial phase. Collecting duct carcinoma is medullary/centrally located and hypovascular. Clear cell RCC generally shows a well-defined pseudocapsule, while collecting duct carcinoma is infiltrative and poorly defined. On MRI, clear cell RCC may show high T2 signal (cystic/necrotic areas) and signal loss on opposed-phase (intracytoplasmic lipid); collecting duct carcinoma shows low T2 signal and no chemical shift signal. Prognosis of clear cell RCC is significantly better.
Distinguishing Feature
Renal lymphoma may also show infiltrative growth pattern and poor enhancement — these features overlap with collecting duct carcinoma. However, lymphoma generally shows bilateral/multifocal involvement, is accompanied by systemic lymphadenopathy, and splenomegaly may be present. On CT, lymphoma is homogeneously hypodense and necrosis is rare — in collecting duct carcinoma, heterogeneous structure and necrosis are common. Pelvicalyceal system invasion is rarer in lymphoma; even if invasion is present, a more diffuse infiltration pattern is seen. Clinically, B symptoms (fever, night sweats, weight loss) are more prominent in lymphoma. Elevated LDH is common in lymphoma.
Distinguishing Feature
Papillary RCC is also a hypovascular tumor showing poor enhancement in the arterial phase — this feature overlaps with collecting duct carcinoma. However, papillary RCC typically locates in the renal cortex (not medullary), shows a well-defined pseudocapsule, and tends to grow exophytically. On MRI, papillary RCC may show low T2 signal (hemosiderin deposition) but high T1 signal (hemorrhagic content) is a characteristic finding of papillary RCC — T1 hyperintensity is not expected in collecting duct carcinoma. Papillary RCC is generally diagnosed at smaller size and earlier stage; its prognosis is significantly better than collecting duct carcinoma.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralCollecting duct carcinoma is a rare but extremely aggressive renal malignancy. Most patients present with advanced-stage disease (stage III-IV) at diagnosis. Radical nephrectomy is the primary treatment, but most patients have low cure rates due to systemic disease. Biopsy is generally necessary for differentiation from urothelial carcinoma and medullary carcinoma — immunohistochemical profile (INI1 status, PAX8, GATA3) is critical in differential diagnosis. Sickle cell trait must be specifically investigated (to exclude medullary carcinoma). Tyrosine kinase inhibitors (TKI) and mTOR inhibitors targeting clear cell RCC are generally ineffective; better responses have been reported with cisplatin/gemcitabine-based combinations (urothelial carcinoma protocols). Early-stage promising results with immunotherapy (checkpoint inhibitors) are available. Multidisciplinary tumor board (urology, oncology, pathology, radiology) evaluation is mandatory. Median survival is 12-30 months with 5-year survival <15%.
Collecting duct carcinoma is an extremely aggressive tumor frequently presenting at advanced stage. Response to chemotherapy is limited. Radical nephrectomy is the primary treatment but prognosis is poor.